Clinical Trials Logo
  1. Home
  2. FSGS
  3. NCT01468493

A Prospective Controlled Study of Serum suPAR in the CsA-treated FSGS Patients — SuparSDRF  

FSGS Clinical Trial

Official title:
A Prospective Controlled Follow-up of Serum Soluble Urokinase Receptor in the Cyclosporine A-treated Patients With Steroid-dependent and Steroid-resistant Focal Segmental Glomerulosclerosis

Clinical Trial Summary

The purpose of this study is to determine whether the improved responsiveness to treatment achieved by CsA in patients with steroid-resistant or steroid-dependent FSGS could be explained by CsA's inhibitory action on the circulating suPAR expression.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

  • FSGS
  • Glomerulosclerosis, Focal Segmental
Clinical Trial Details
NCT number NCT01468493
Study type Observational
Source Guangdong General Hospital
Contact Wei Shi, MD,PhD
Phone 86-20-8385-0849
Email weishi_gz@126.com
Status Recruiting
Phase N/A
Start date January 2011
Completion date January 2019
View Details
See also
  Status Clinical Trial Phase
Completed NCT04009668 - Tumor Necrosis Factor Inhibition in Focal Segmental Glomerulosclerosis and Treatment Resistant Minimal Change Disease Phase 2
Terminated NCT01451489 - The Efficacy and Safety of Tacrolimus in Treated Refractory Focal Segmental Glomerulosclerosis N/A
Recruiting NCT05183646 - A Study of the Efficacy and Safety of DMX-200 in Patients With FSGS Who Are Receiving an ARB Phase 3
Completed NCT03536754 - A Study of CCX140-B in Subjects With FSGS Phase 2
Withdrawn NCT02399462 - Acthar for Treatment of Post-transplant FSGS Phase 4
Enrolling by invitation NCT04571658 - NEPTUNE Match Study
Recruiting NCT05508009 - Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor Phase 1/Phase 2
Terminated NCT01164098 - Rituximab to Prevent Recurrence of Proteinuria Phase 3
Active, not recruiting NCT02683889 - Use of Acthar in Patients With FSGS That Will be Undergoing Renal Transplantation Phase 3
Recruiting NCT05650619 - Recurrence Post-transplant Observational Study in Focal Segmental Glomerulosclerosis and Minimal Change Disease
Recruiting NCT05383547 - Bortezomib for Treating Glomerular Diseases N/A
Recruiting NCT05505500 - Interview Study of Adult and Child Patients and Parents of Children With Swelling Due to Nephrotic Syndrome.